Piramal Pharma Limited (PPL) is a leading player in the global pharmaceutical industry, renowned for its innovative solutions and extensive reach. With 17 advanced manufacturing facilities and a vast distribution network spanning over 100 countries, PPL delivers high-quality products and services worldwide. Its divisions, including Piramal Pharma Solutions (PPS) and Piramal Critical Care (PCC), cater to diverse healthcare needs, while strategic partnerships, such as AbbVie Therapeutics India Private Limited, bolster its capabilities. A 20% strategic growth investment from the Carlyle Group in October 2020 further solidified PPL’s position, enhancing its global presence and contributing to its ongoing success as part of the esteemed Piramal Group.
About Piramal Pharma
Piramal Pharma Limited (PPL) operates at the forefront of the pharmaceutical industry, offering a comprehensive range of products and services globally. With 17 cutting-edge development and manufacturing facilities and a robust distribution network spanning over 100 countries, PPL is committed to delivering innovative healthcare solutions. Its divisions, including Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and India Consumer Healthcare, cater to diverse healthcare needs, from contract development and manufacturing to complex hospital generics and over-the-counter products. PPL’s strategic partnerships, such as AbbVie Therapeutics India Private Limited, enhance its capabilities and contribute to its position as a leader in the pharmaceutical landscape. As part of the prestigious Piramal Group, PPL leverages its global presence and a diverse workforce of over 10,000 professionals to drive forward its mission of advancing healthcare worldwide.
Piramal Pharma’s Q4 FY24 Results Highlight
- The remarkable 102.1% year-on-year increase in net profit for Q4 FY24 underscores Piramal Pharma’s strong financial performance and effective business strategies.
- Revenue from operations surged by 18% to ₹2,552.4 crore, indicating Strong market traction and operational efficiency, aligning with the company’s growth objectives.
- The significant improvement in EBITDA by 50.9% to ₹529.9 crore reflects Piramal Pharma’s ability to generate higher earnings from its operations.
- The notable increase in EBITDA margin to 20.8% in Q4 FY24 highlights the company’s improved profitability and operational effectiveness.
- The improvement in the net debt to EBITDA ratio from 5.6x to 2.9x signifies Piramal Pharma’s prudent financial management and strengthened balance sheet.
- The board’s recommendation of a final dividend of ₹0.11 per equity share for FY24 underscores the company’s commitment to enhancing shareholder value and rewarding investors.
- Nandini Piramal, Chairperson of Piramal Pharma, expressed satisfaction with the company’s strong performance, particularly highlighting the Strong 19% year-on-year revenue growth in the CDMO business and increased order inflows, indicating positive market demand and customer confidence.
- The positive financial results reflect Piramal Pharma’s resilience, operational excellence, and strategic focus on delivering long-term value to its stakeholders.
How to Purchase Piramal Pharma Shares in India?
Below are the trading platforms that you can use to purchase Piramal Pharma shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
Piramal Pharma Share Price Target 2024, 2025 to 2030
Piramal Pharma Share Price Target 2024
| When | Maximum Price | Minimum Price |
| August 2024 | 189.35 | 164.66 |
| September 2024 | 196.93 | 171.24 |
| October 2024 | 193.07 | 167.88 |
| November 2024 | 200.79 | 174.60 |
| December 2024 | 202.80 | 176.35 |
In 2024, Piramal Pharma’s maximum and minimum prices are expected to vary as follows: in August, the prices are projected to range between ₹189.35 and ₹164.66; in September, they are expected to be between ₹196.93 and ₹171.24; in October, the prices may range from ₹193.07 to ₹167.88; in November, the forecasted prices are between ₹200.79 and ₹174.60; and in December, the prices are anticipated to be between ₹202.80 and ₹176.35.
Piramal Pharma Share Price Prediction 2025
| When | Maximum Price | Minimum Price |
| January 2025 | 204.83 | 157.56 |
| February 2025 | 206.89 | 159.15 |
| March 2025 | 211.24 | 162.49 |
| April 2025 | 209.15 | 160.88 |
| May 2025 | 203.06 | 156.20 |
| June 2025 | 212.19 | 163.23 |
| July 2025 | 208.03 | 160.03 |
| August 2025 | 214.47 | 164.97 |
| September 2025 | 217.04 | 166.95 |
| October 2025 | 222.68 | 171.29 |
| November 2025 | 228.25 | 175.58 |
| December 2025 | 238.52 | 183.48 |
As we step into 2025, Piramal Pharma’s projected monthly prices reflect a steady upward trend. In January, the maximum price is expected to be ₹204.83 and the minimum ₹157.56. By December, the maximum price is projected to reach ₹238.52, with a minimum of ₹183.48. This positive trajectory indicates strong growth potential for Piramal Pharma throughout the year.
Piramal Pharma Share Price Target 2026
| When | Maximum Price | Minimum Price |
| January 2026 | 245.68 | 188.98 |
| February 2026 | 239.54 | 184.26 |
| March 2026 | 244.33 | 187.94 |
| April 2026 | 249.31 | 191.78 |
| May 2026 | 246.84 | 189.88 |
| June 2026 | 253.02 | 194.63 |
| July 2026 | 248.05 | 190.81 |
| August 2026 | 255.73 | 196.71 |
| September 2026 | 260.84 | 200.65 |
| October 2026 | 267.62 | 205.86 |
| November 2026 | 274.31 | 211.01 |
| December 2026 | 281.17 | 216.29 |
Piramal Pharma Share Price Prediction 2027
| When | Maximum Price | Minimum Price |
| January 2027 | 283.98 | 218.45 |
| February 2027 | 291.26 | 224.05 |
| March 2027 | 302.62 | 232.79 |
| April 2027 | 296.69 | 228.22 |
| May 2027 | 288.05 | 221.58 |
| June 2027 | 301.01 | 231.55 |
| July 2027 | 295.11 | 227.01 |
| August 2027 | 304.24 | 234.03 |
| September 2027 | 314.88 | 242.22 |
| October 2027 | 323.07 | 248.52 |
| November 2027 | 331.15 | 254.73 |
| December 2027 | 339.43 | 261.10 |
Piramal Pharma Share Price Target 2028
| When | Maximum Price | Minimum Price |
| January 2028 | 346.21 | 266.32 |
| February 2028 | 355.09 | 273.15 |
| March 2028 | 368.94 | 283.80 |
| April 2028 | 361.71 | 278.24 |
| May 2028 | 351.17 | 270.13 |
| June 2028 | 366.97 | 282.29 |
| July 2028 | 359.78 | 276.75 |
| August 2028 | 370.91 | 285.31 |
| September 2028 | 383.89 | 295.30 |
| October 2028 | 393.87 | 302.98 |
| November 2028 | 403.71 | 310.55 |
| December 2028 | 413.81 | 318.31 |
Piramal Pharma Share Price Target 2029
| When | Maximum Price | Minimum Price |
| January 2029 | 422.08 | 324.68 |
| February 2029 | 432.91 | 333.00 |
| March 2029 | 449.79 | 345.99 |
| April 2029 | 440.97 | 339.21 |
| May 2029 | 428.13 | 329.33 |
| June 2029 | 447.39 | 344.15 |
| July 2029 | 438.62 | 337.40 |
| August 2029 | 452.19 | 347.83 |
| September 2029 | 468.01 | 360.01 |
| October 2029 | 480.18 | 369.37 |
| November 2029 | 492.18 | 378.60 |
| December 2029 | 504.49 | 388.07 |
Piramal Pharma Share Price Target 2030
| When | Maximum Price | Minimum Price |
| January 2030 | 514.58 | 395.83 |
| February 2030 | 527.77 | 405.98 |
| March 2030 | 548.36 | 421.81 |
| April 2030 | 537.60 | 413.54 |
| May 2030 | 521.95 | 401.50 |
| June 2030 | 545.43 | 419.56 |
| July 2030 | 534.74 | 411.34 |
| August 2030 | 551.28 | 424.06 |
| September 2030 | 570.57 | 438.90 |
| October 2030 | 585.41 | 450.31 |
| November 2030 | 600.04 | 461.57 |
| December 2030 | 615.04 | 473.11 |
As we look ahead to 2030, Piramal Pharma’s projected monthly prices indicate a steady increase. In January, the highest expected price is ₹514.58, while the lowest is ₹395.83. By December, the forecasted maximum price rises to ₹615.04, with a minimum of ₹473.11.
Financial Condition of Piramal Pharma
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 6,315 | 6,559 | 7,082 | 8,171 |
| Expenses + | 4,887 | 5,609 | 6,453 | 6,975 |
| Operating Profit | 1,428 | 950 | 629 | 1,196 |
| OPM % | 23% | 14% | 9% | 15% |
| Other Income + | 230 | 319 | 272 | 172 |
| Interest | 163 | 198 | 344 | 448 |
| Depreciation | 545 | 586 | 677 | 741 |
| Profit before tax | 949 | 485 | -120 | 179 |
| Tax % | 12% | 22% | -55% | 90% |
| Net Profit + | 835 | 376 | -186 | 18 |
| EPS in Rs | -1.41 | 0.13 | ||
| Dividend Payout % | 0% | 18% | 0% | 0% |
Piramal Pharma’s financial journey reflects a compelling narrative of resilience, growth, and strategic adaptation. The company has navigated through a dynamic market landscape, marked by both opportunities and challenges, showcasing commendable agility and foresight in its operations. Despite the evolving industry dynamics, Piramal Pharma has consistently charted an upward trajectory in its sales revenue, ascending from ₹6,315 crore in March 2021 to an impressive ₹8,171 crore in March 2024. This sustained growth underscores the company’s ability to capture market demand and capitalize on emerging trends.
However, amidst this overarching growth narrative, Piramal Pharma has encountered fluctuations in its operating profit, illustrating the complexities inherent in managing a diversified portfolio of products and services. From a peak of ₹1,428 crore in March 2021, the operating profit experienced a downturn to ₹629 crore in March 2023, before rebounding to ₹1,196 crore in March 2024. Such oscillations underscore the company’s dynamic response to market shifts and its proactive measures to enhance operational efficiency and cost optimization strategies.
Similarly, the net profit trajectory reflects a narrative of resilience and adaptability. While the company witnessed positive figures in March 2021 and March 2022, the net profit turned negative in March 2023, primarily attributed to increased expenses. However, Piramal Pharma swiftly recovered, with the net profit reaching ₹18 crore by March 2024, a testament to its robust financial management and strategic resilience.
Throughout these financial fluctuations, Piramal Pharma has remained steadfast in its commitment to shareholders, maintaining a conservative dividend payout policy. Despite the challenges encountered, the company has endeavored to reward its shareholders, exemplifying its unwavering dedication to long-term value creation and sustainability.
Furthermore, the fluctuation in operating profit margin (OPM) percentage, ranging from 9% in March 2023 to 23% in March 2021, highlights the dynamic nature of operational efficiencies and cost management strategies within Piramal Pharma. These fluctuations underscore the company’s continuous pursuit of excellence and optimization, positioning it strategically for sustained growth and market leadership in the pharmaceutical landscape.
FAQS
What is the current share price of Piramal Pharma?
As of August 08th, 2024, the share price of Piramal Pharma is around INR ₹179.
What is the expected share price target of Piramal Pharma by 2024?
Based on various market analyses and expert opinions, the expected share price target of Piramal Pharma by 2024 is around INR 202.80.
Can Piramal Pharma share price reach INR 500 by 2025?
It is unlikely for the share price of Piramal Pharma to reach INR 500 by 2025. Such a target would require a massive and unrealistic growth rate.
What is Piramal Pharma share price target for 2025?
As per our analysis, Piramal Pharma in 2025 is expected to trade between ₹156.20 to ₹238.52.
What is Piramal Pharma share price target for 2030?
As per our analysis, Piramal Pharma share price target for 2030 would be somewhere between ₹395.83 and ₹615.04.
Also Read
- Piramal Enterprises Share Price Target 2024, 2025 to 2030
- Dr Lal PathLabs Share Price Target: 2024, 2025, 2026 to 2030
- BHARAT FORGE SHARE PRICE TARGET 2024, 2025, 2026 TO 2030
Conclusion
In summary, Piramal Pharma Limited’s Q4 FY24 results demonstrate a robust performance, characterized by significant increases in net profit, revenue from operations, and EBITDA. The company’s strategic investments and focus on innovation have propelled its growth trajectory, as evidenced by its strong financials. Despite fluctuations in operating profit and net profit in previous years, Piramal Pharma has exhibited resilience and adaptability, reflected in its improved financial stability and conservative dividend payout policy. Looking forward, with its strong market position, diverse product portfolio, and strategic partnerships, Piramal Pharma is well-equipped to capitalize on growth opportunities within the pharmaceutical industry.
Having said that, we are not a financial advisor. Please consult a SEBI-registered financial advisor before trading Piramal Pharma. This post on Piramal Pharma share price target from 2024 to 2030 is for educational purposes only.
Leave a Reply